Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)

Abstract Background Galcanezumab is approved in the European Union (EU) as migraine prophylaxis in adults with at least four migraine days per month. The aim of this retrospective observational study was to evaluate the long-term effectiveness of galcanezumab on migraine-related burdens and its impa...

詳細記述

書誌詳細

出版年:	Neurology and Therapy
主要な著者:	Fabrizio Vernieri, Luigi Francesco Iannone, Simona Guerzoni, Antonio Russo, Piero Barbanti, Grazia Sances, Sabina Cevoli, Renata Rao, Carlo Lovati, Anna Ambrosini, Carlotta Buzzoni, Federico Battisti, Laura Vatteone, Steffy Martin Luther King, Federico Torelli
フォーマット:	論文
言語:	英語
出版事項:	Adis, Springer Healthcare 2024-02-01
主題:	Galcanezumab Migraine Migraine prevention Calcitonin gene-related peptide Monoclonal antibodies Long-term treatment
オンライン･アクセス:	https://doi.org/10.1007/s40120-024-00582-0